3 High-Yield Dividend Stocks to Buy in October
Briefly

3 High-Yield Dividend Stocks to Buy in October
"To investors, the stock market is considered one of if not the greatest ways to build wealth. While no asset can guarantee returns, the stock market has performed significantly well over the past decade. There are thousands of companies to choose from, and there's a chance a few of those could help you achieve your goals. If you're someone who likes to make your money work for you, consider investing in dividend stocks."
"Dividend yield: 6.28% Pharmaceutical company Pfizer is one of the best dividend stocks to own this month. The stock offers a juicy yield of 6.28%, significantly higher than the 1.25% average yield of the S&P 500. While the stock has suffered after the pandemic, it is gaining ground and has built a cost-savings plan. Revenue and net income (aka profit) have both declined significantly since 2022, and the company has been punished for its own success."
"Despite the ups and downs, Pfizer is a company that has grown stronger in the past two years. Exchanging hands for $27, PFE is up 2.8% in 2025. The company has earned approval for medicines in the past few years and has recently acquired Metsera, a biotech company working on weight management medicines. The demand for anti-obesity therapies is growing, and Metsera has a leading candidate that has performed well in two mid-stage studies."
The stock market remains a leading method to build wealth, though no asset guarantees returns. Dividend stocks can generate regular income and contribute to long-term capital appreciation. High-quality dividend payers with yields above 6% can support monthly expenses and enhance total returns. Pfizer offers a 6.28% yield and has faced revenue and profit declines since 2022, but has implemented cost-savings measures and advanced new drug approvals. The company acquired Metsera to pursue weight-management therapies, benefiting from growing demand for anti-obesity treatments and promising mid-stage clinical results.
Read at 24/7 Wall St.
Unable to calculate read time
[
|
]